Posted by Michael Wonder on 24 Feb 2026
Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus (semaglutide medicines), building on continued efforts to expand access
24 February 2026 - Today, Novo Nordisk announced that, effective 1 January 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus (semaglutide) tablets 7 mg or 14 mg to $675, representing reductions of approximately 50% and 35% for Wegovy and Ozempic, respectively, from the current list price.
This decision applies to all doses of these medicines and reflects Novo Nordisk’s commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US health care system.
